(BSX) Boston Scientific - Ratings and Ratios
Stents, Catheters, Pacemakers, Defibrillators, Lasers
BSX EPS (Earnings per Share)
BSX Revenue
Description: BSX Boston Scientific
Boston Scientific Corp (NYSE:BSX) designs, manufactures, and markets a broad range of medical devices across two primary segments-MedSurg and Cardiovascular-serving interventional specialties worldwide. The firm, founded in 1979 and based in Marlborough, Massachusetts, leverages a diversified product slate that spans gastrointestinal, urological, neurological, and cardiac therapies.
Within MedSurg, the company offers gastrointestinal tools (e.g., resolution clips, biliary stents, single-use duodenoscopes), urology solutions (ureteral stents, digital flexible ureteroscopes, holmium lasers, penile implants), and neuromodulation technologies (spinal cord stimulators, deep-brain stimulation systems). The Cardiovascular segment includes coronary disease and aortic valve devices, the WATCHMAN FLX left-atrial appendage closure system, and a suite of implantable cardiac rhythm management products such as CRT-D/CRT-P pacemakers, MRI-compatible sub-cutaneous ICDs, and remote monitoring platforms.
Key performance indicators suggest solid momentum: FY 2023 revenue reached roughly $12.6 billion, with MedSurg contributing about 55% and delivering a 23% operating margin, while Cardiovascular posted a 21% margin. R&D intensity remains near 9% of sales, reflecting continued pipeline investment. Sector-wide drivers-an aging U.S. population, rising prevalence of chronic cardiovascular and gastrointestinal conditions, and a projected 5% CAGR in global healthcare spending-support demand growth for BSX’s high-margin devices.
For a deeper, data-driven assessment of Boston Scientific’s valuation and risk profile, you may find ValueRay’s analytical dashboards useful.
BSX Stock Overview
| Market Cap in USD | 141,374m |
| Sub-Industry | Health Care Equipment |
| IPO / Inception | 1992-05-18 |
BSX Stock Ratings
| Growth Rating | 80.6% |
| Fundamental | 69.6% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -2.13% |
| Analyst Rating | 4.59 of 5 |
BSX Dividends
Currently no dividends paidBSX Growth Ratios
| Growth Correlation 3m | -70.4% |
| Growth Correlation 12m | 58.4% |
| Growth Correlation 5y | 93.9% |
| CAGR 5y | 34.82% |
| CAGR/Max DD 3y (Calmar Ratio) | 2.24 |
| CAGR/Mean DD 3y (Pain Ratio) | 13.83 |
| Sharpe Ratio 12m | 0.30 |
| Alpha | 1.20 |
| Beta | 0.614 |
| Volatility | 19.98% |
| Current Volume | 7945.3k |
| Average Volume 20d | 9434.1k |
| Stop Loss | 94.8 (-3%) |
| Signal | 0.33 |
Piotroski VR‑10 (Strict, 0-10) 8.0
| Net Income (2.50b TTM) > 0 and > 6% of Revenue (6% = 1.11b TTM) |
| FCFTA 0.08 (>2.0%) and ΔFCFTA 3.23pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 10.44% (prev 22.43%; Δ -11.98pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.10 (>3.0%) and CFO 4.29b > Net Income 2.50b (YES >=105%, WARN >=100%) |
| Net Debt (11.49b) to EBITDA (4.71b) ratio: 2.44 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.37 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (1.49b) change vs 12m ago 0.61% (target <= -2.0% for YES) |
| Gross Margin 63.23% (prev 62.04%; Δ 1.18pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 47.02% (prev 41.04%; Δ 5.98pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 8.51 (EBITDA TTM 4.71b / Interest Expense TTM 399.0m) >= 6 (WARN >= 3) |
Altman Z'' 1.40
| (A) 0.05 = (Total Current Assets 7.12b - Total Current Liabilities 5.19b) / Total Assets 41.56b |
| (B) 0.10 = Retained Earnings (Balance) 4.14b / Total Assets 41.56b |
| (C) 0.09 = EBIT TTM 3.40b / Avg Total Assets 39.33b |
| (D) 0.18 = Book Value of Equity 3.44b / Total Liabilities 18.91b |
| Total Rating: 1.40 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 69.55
| 1. Piotroski 8.0pt = 3.0 |
| 2. FCF Yield 2.17% = 1.08 |
| 3. FCF Margin 17.90% = 4.48 |
| 4. Debt/Equity 0.54 = 2.36 |
| 5. Debt/Ebitda 2.44 = -0.84 |
| 6. ROIC - WACC (= 1.07)% = 1.33 |
| 7. RoE 11.49% = 0.96 |
| 8. Rev. Trend 98.78% = 7.41 |
| 9. EPS Trend -4.37% = -0.22 |
What is the price of BSX shares?
Over the past week, the price has changed by +0.51%, over one month by -1.21%, over three months by -5.24% and over the past year by +12.39%.
Is Boston Scientific a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of BSX is around 108.42 USD . This means that BSX is currently undervalued and has a potential upside of +10.88% (Margin of Safety).
Is BSX a buy, sell or hold?
- Strong Buy: 23
- Buy: 8
- Hold: 3
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the BSX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 124.9 | 27.7% |
| Analysts Target Price | 124.9 | 27.7% |
| ValueRay Target Price | 120 | 22.7% |
Last update: 2025-10-13 02:05
BSX Fundamental Data Overview
P/E Trailing = 56.7917
P/E Forward = 28.49
P/S = 7.6443
P/B = 6.3598
P/EG = 1.4736
Beta = 0.614
Revenue TTM = 18.49b USD
EBIT TTM = 3.40b USD
EBITDA TTM = 4.71b USD
Long Term Debt = 10.98b USD (from longTermDebt, last quarter)
Short Term Debt = 480.0m USD (from shortTermDebt, last quarter)
Debt = 12.03b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 11.49b USD (from netDebt column, last quarter)
Enterprise Value = 152.87b USD (141.37b + Debt 12.03b - CCE 534.0m)
Interest Coverage Ratio = 8.51 (Ebit TTM 3.40b / Interest Expense TTM 399.0m)
FCF Yield = 2.17% (FCF TTM 3.31b / Enterprise Value 152.87b)
FCF Margin = 17.90% (FCF TTM 3.31b / Revenue TTM 18.49b)
Net Margin = 13.53% (Net Income TTM 2.50b / Revenue TTM 18.49b)
Gross Margin = 63.23% ((Revenue TTM 18.49b - Cost of Revenue TTM 6.80b) / Revenue TTM)
Gross Margin QoQ = 67.65% (prev 63.26%)
Tobins Q-Ratio = 3.68 (Enterprise Value 152.87b / Total Assets 41.56b)
Interest Expense / Debt = 0.75% (Interest Expense 90.0m / Debt 12.03b)
Taxrate = 15.52% (146.0m / 941.0m)
NOPAT = 2.87b (EBIT 3.40b * (1 - 15.52%))
Current Ratio = 1.37 (Total Current Assets 7.12b / Total Current Liabilities 5.19b)
Debt / Equity = 0.54 (Debt 12.03b / totalStockholderEquity, last quarter 22.42b)
Debt / EBITDA = 2.44 (Net Debt 11.49b / EBITDA 4.71b)
Debt / FCF = 3.47 (Net Debt 11.49b / FCF TTM 3.31b)
Total Stockholder Equity = 21.78b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.02% (Net Income 2.50b / Total Assets 41.56b)
RoE = 11.49% (Net Income TTM 2.50b / Total Stockholder Equity 21.78b)
RoCE = 10.37% (EBIT 3.40b / Capital Employed (Equity 21.78b + L.T.Debt 10.98b))
RoIC = 8.75% (NOPAT 2.87b / Invested Capital 32.81b)
WACC = 7.68% (E(141.37b)/V(153.40b) * Re(8.28%) + D(12.03b)/V(153.40b) * Rd(0.75%) * (1-Tc(0.16)))
Discount Rate = 8.28% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.55%
[DCF Debug] Terminal Value 80.68% ; FCFE base≈2.69b ; Y1≈3.32b ; Y5≈5.66b
Fair Price DCF = 62.07 (DCF Value 91.98b / Shares Outstanding 1.48b; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: -4.37 | EPS CAGR: -56.44% | SUE: -4.0 | # QB: 0
Revenue Correlation: 98.78 | Revenue CAGR: 18.54% | SUE: 3.99 | # QB: 7
Additional Sources for BSX Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle